However, inappropriate treatment due to incorrect identification of pathogen contribute to the limited use of current drugs in the management of CABP. For instance, according to an article published in November 2019 in the National Center for Biotechnology Information (NCBI), the presence of multiple pathogens in patients leads to incorrect selection of initial antibiotic, which may affect the mortality outcome in CABP. Such inappropriate medication are expected to hamper the market growth.
Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients